CytoSorbents Receives Additional $5 Million in Non-Dilutive Debt Financing from Bridge Bank
CytoSorbents Corporation, a leader in critical care immunotherapy specializing in blood purification, received an additional $5 million from the Life Sciences Group of Bridge Bank.
CytoSorbents Corporation (“CytoSorbents” or the “Company”) and its U.S. operating subsidiary, CytoSorbents Medical, Inc. began working with Bridge Bank in June, 2016 when they secured an initial $5 million term loan. On June 30, 2017 the Company expanded its relationship to secure an additional $5 million of funding available under their agreement, totaling it’s borrowings to $10 million. The Company intends to use the loan to provide working capital to fund ongoing operations and support clinical trials.
"With our existing cash on hand, this non-dilutive financing further strengthens our balance sheet at an attractive cost of capital and provides sufficient working capital for the foreseeable future, allowing us to continue to pursue our aggressive growth strategy and clinical trial objectives as we increase product sales worldwide and move closer to operating cash flow breakeven,” stated Kathleen Bloch, CPA, MBA, chief financial officer of CytoSorbents Corporation. “We welcome this continuation and expansion of our important relationship with Bridge Bank, a reputable and premier industry provider with a broad scope of financial services.”
“We’ve been working with CytoSorbents for over a year now and believe they possess a truly innovative technology in the life sciences space which could transform critical care medicine and cardiac surgery and save lives throughout the world,” said Justin McDonie, senior vice president for Bridge Bank. “We are pleased to provide this additional capital to support CytoSorbents’ growth at this important juncture in their evolution.”
ABOUT BRIDGE BANK
Bridge Bank is a division of Western Alliance Bank, Member FDIC, the go-to bank for business in its growing markets. Bridge Bank was founded in 2001 in Silicon Valley to offer a better way to bank for small-market and middle-market businesses across many industries, as well as emerging technology companies and the private equity community. Geared to serving both venture-backed and non-venture-backed companies, Bridge Bank offers a broad scope of financial solutions including growth capital, equipment and working capital credit facilities, sustainable energy project finance, venture debt, treasury management, asset-based lending, SBA and commercial real estate loans, ESOP finance and a full line of international products and services. Based in San Jose, Bridge Bank has eight offices in major markets across the country along with Western Alliance Bank’s robust national platform of specialized financial services. Western Alliance Bank is the primary subsidiary of Phoenix-based Western Alliance Bancorporation. One of the country’s top-performing banking companies, Western Alliance ranks #4 on the Forbes 2017 “Best Banks in America” list.
ABOUT CYTOSORBENTS CORPORATION (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 43 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury and pancreatitis, as well as in cancer immunotherapy. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. CytoSorbents has completed its REFRESH (REduction in FREe Hemoglobin) 1 trial – a multi-center, randomized controlled study that has demonstrated the safety and efficacy of free hemoglobin reduction with intra-operative CytoSorb® use in a heart-lung machine during complex cardiac surgery. In 2017, the company plans to initiate a pivotal REFRESH 2 trial intended to support U.S. FDA approval. CytoSorb® has been used safely in more than 23,000 human treatments to date.
CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding in excess of $19 million from DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM) and others. The Company has numerous products under development based upon this unique blood purification technology, protected by 32 issued U.S. patents and multiple applications pending, including CytoSorb-XL™, HemoDefend™, VetResQ™, ContrastSorb, DrugSorb, and others. For more information, please visit the Company’s websites at www.cytosorbents.com and www.cytosorb.com or follow us on Facebook and Twitter
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 3, 2017, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
Recent NewsBridge Bank Provides Senior Debt Financing to Support the Leveraged Buyout of Trade Supplies, LLC by Sole Source CapitalBridge Bank Welcomes Bob Curley as Chief Credit OfficerBridge Bank Upsizes Capstone Turbine Facility to $15 MillionRestoration Robotics Secures $20 Million Loan and Security Agreement with Solar Capital Ltd. and Bridge BankCytoSorbents Refinances Existing Debt with New $15 Million Debt Facility with Bridge Bank
Recent InsightsDon't Get Hooked: How to Spot a Phishing EmailThe Biggest Trends in Hotel Franchising - 2017 EditionThe Key to Wire Fraud Prevention: Out-of-Band AuthenticationMobile Banking Helps Businesses On The GoConsider the Business Benefits of Payroll Cards — and Keep Employees Happy
"We know our clients and this market, and what's motivating this management team to innovate and persevere just add… twitter.com/i/web/status/1… - 3 daysWe are proud to support @Rhythmix1 as a sponsor of their Pour Your heART Out Benefit for the Arts Celebration takin… twitter.com/i/web/status/1… - 1 week 3 days agoMarkets look to remaining monthly data amidst trade disputes. westernalliancebancorporation.com/bridge-bank-ho… - 1 week 4 days agoWe are proud to sponsor the @LosAltosChamber 29th Annual Golf Tournament today. We hope all of the golfers particip… twitter.com/i/web/status/1… - 1 week 6 days agoLifting up our communities is important to the people of Western Alliance. We live this value in many ways, startin… twitter.com/i/web/status/1… - 2 weeks 3 days agoStarting from scratch in 2006, @RevolutionFoods has grown to now serve two million healthy meals per week in 1,000+… twitter.com/i/web/status/1… - 2 weeks 4 days ago"Revolution Foods is a perfect example of a client that came to us early in the company's life cycle, and we have c… twitter.com/i/web/status/1… - 3 weeks 3 days agoTomorrow night, Dale Marie Golden of @bridgebank will be speaking at the Oakland Empowerment Scholarship & Mentorin… twitter.com/i/web/status/1… - about 1 month agoOur #LifeSciences group recently helped @RareCyte, a #biotechnology company working to advance the boundaries of bi… twitter.com/i/web/status/1… - about 1 month 1 day agoBridge Bank is a division of Western Alliance Bank. Western Alliance was named #2 on the Forbes 2018 Best Banks in… twitter.com/i/web/status/1… - about 1 month 2 days agoBridge Bank is excited to be sponsoring the return of #PACTcapcon on Sept 26! twitter.com/PhilaPACT/stat… - about 1 month 3 days agoOur #LifeSciences Group is pleased to announce their recently funded deal with @abscibio, a #biomanufacturing compa… twitter.com/i/web/status/1… - about 1 month 2 weeks agoHappy birthday, #America! Your friends at Bridge Bank wish everyone a safe and joyous celebration! REMINDER: In o… twitter.com/i/web/status/1… - about 1 month 2 weeks agoOur #LifeSciences Group is pleased to announce their latest deal with @ardelyx, a #biotechnology company committed… twitter.com/i/web/status/1… - about 1 month 3 weeks ago#Dollar rallies to 11 month highs on rising interest rates and #EconomicGrowth westernalliancebancorporation.com/bridge-bank-ho… - about 1 month 4 weeks agoOur #LifeSciences Group is excited to announce their most recent transaction with @ARTASHair, offering the first an… twitter.com/i/web/status/1… - about 1 month 4 weeks agoDid you know? Bernard J. Cigrand is considered to be the “Father of Flag Day.” In 1885, he organized a group of sch… twitter.com/i/web/status/1… - about 2 months 5 days agoOur #LifeSciences Group is pleased to announce their most recent transaction with @Zipline_Medical a technology com… twitter.com/i/web/status/1… - about 2 months 7 days agoDue to the close proximity of the Golden State Warriors Championship Parade and activities, our Oakland branch will… twitter.com/i/web/status/1… - about 2 months 1 week agoCongratulations to the @warriors on their back-to-back championship! Our employees in Oakland are very excited that… twitter.com/i/web/status/1… - about 2 months 1 week agoWe were proud to sponsor last night’s SPUR event at San Pedro Market in downtown San Jose. You can learn more about… twitter.com/i/web/status/1… - about 2 months 1 week agoAs presenting sponsor of the 8th Annual #sjsueconsummit we want to extend our gratitude and many #thanks to those w… twitter.com/i/web/status/1… - about 2 months 2 weeks agoAre you wondering how the #economy can be as #healthy as ever if a lack of #housing is the #1 concern? You’re not a… twitter.com/i/web/status/1… - about 2 months 3 weeks agoOn May 31, Dr. Christopher Thornberg, founder of Beacon Economics, will be at #sjsueconsummit providing an analysis… twitter.com/i/web/status/1… - about 2 months 3 weeks agoCalifornia is now the 5th largest economy in the world, surpassing the UK. On 5/31, Dr. Thornberg, founder of Beaco… twitter.com/i/web/status/1… - about 2 months 3 weeks agoThis #MemorialDay, we honor those who lost their lives to give us #freedom. pic.twitter.com/lKEzeg9YarHave you ever been in a car with a driver who has one foot on the accelerator and the other on the brakes? On 5/31,… twitter.com/i/web/status/9… - about 2 months 3 weeks agoWe are a proud sponsor of the 19th Annual B. Riley FBR #InstitutionalInvestorConference, taking place May 23 - 24,… twitter.com/i/web/status/9… - about 2 months 3 weeks agoOur Life Sciences Group is excited to announce Alastin Skincare, an innovative skincare company that has designed a… twitter.com/i/web/status/9… - about 2 months 4 weeks agoinfo.bridgebank.com/economicsummit - about 3 months 1 week ago There's still time to register for the #sjsueconsummit featuring an analysis and forecast… twitter.com/i/web/status/9… - about 3 months 1 week agoAs a sponsor of the @PhilaPACT Enterprise Awards 25th Anniversary Dinner, we would like to congratulate our clients… twitter.com/i/web/status/9… - about 3 months 1 week agoBridge Bank is a proud sponsor of the Blacks 'n Business Blacks 'n Technology Awards Ceremony tonight. Congratulati… twitter.com/i/web/status/9… - about 3 months 2 weeks agoThank you @eastbayeda and @Oakland for hosting a great panel discussion during #smallbusinessweek twitter.com/eastbayeda/sta… - about 3 months 2 weeks agoinfo.bridgebank.com/economicsummit - about 3 months 2 weeks ago There's still time to register for the #sjsueconsummit featuring an analysis and forecast… twitter.com/i/web/status/9… - about 3 months 2 weeks ago